Lung and splenic B cells facilitate diverse effects on in vitro measures of antitumor immune responses

Cancer Immunity

Volumn 8, Issue , 2008, Pages

  Jones, Harlan P ^a   Wang, Yi Chong ^a,b   Aldridge, Beau ^a,b   Weiss, Jay M ^a,b  

^a UNIVERSITY OF NORTH TEXAS HEALTH SCIENCE CENTER   (United States)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

B lymphocytes; Cancer; Immunologic cytotoxicity; Lung; MADB106; Rats; Spleen

Indexed keywords

B7 ANTIGEN; CD86 ANTIGEN; GAMMA INTERFERON;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN EXPRESSION; ANTINEOPLASTIC ACTIVITY; ARTICLE; B LYMPHOCYTE; CELL COMPARTMENTALIZATION; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOKINE RELEASE; FEMALE; IMMUNE RESPONSE; IN VITRO STUDY; LUNG ALVEOLUS CELL; LUNG METASTASIS; LYMPHOCYTE CULTURE; MALE; NONHUMAN; RAT; SPLEEN CELL; TUMOR CELL DESTRUCTION;

EID: 40849147416     PISSN: None     EISSN: 14249634     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Foss FM. Immunologic mechanisms of antitumor activity. Semin Oncol 2002; 29(3 Suppl 7): 5-11.
2. Qin Z, Richter G, Schuler T, Ibe S, Cao X, Blankenstein T. B cells inhibit induction of T cell-dependent tumor immunity. Nat Med 1998; 4: 627-630.
3. Quan N, Zhang Z, Demetrikopoulos MK, Kitson RP, Chambers WH, Goldfarb RH, Weiss JM. Evidence for involvement of B lymphocytes in the surveillance of lung metastasis in the rat. Cancer Res 1999; 59: 1080-1089.
4. Demetrikopoulos MK, Goldfarb RH, Zhang ZB, Weiss JM. Blood level of B and CD4+ lymphocytes measured before induction of an experimental tumor in rats predicts tumor progression and survival. Cancer Epidemiol Biomarkers Prev 2000; 9: 609-617.
5. Attanavanich K, Kearney JF. Marginal zone, but not follicular B cells, are potent activators of naive CD4 T cells. J Immunol 2004; 172: 803-811.
6. Schneider-Brachert W, Tchikov V, Merkel O, Jakob M, Hallas C, Kruse ML, Groitl P, Lehn A, Hildt E, Held-Feindt J, Dobner T, Kabelitz D, Kronke M, Schutze S. Inhibition of TNF receptor 1 internalization by adenovirus 14.7K as a novel immune escape mechanism. J Clin Invest 2006; 116: 2901-2913.
7. Majima T, Ichikura T, Chochi K, Kawabata T, Tsujimoto H, Sugasawa H, Kuranaga N, Takayama E, Kinoshita M, Hiraide H, Seki S, Mochizuki H. Exploitation of interleukin-18 by gastric can-cers for their growth and evasion of host immunity. Int J Cancer 2006; 118: 388-395.
8. Boussiotis VA, Freeman GJ, Gribben JG, Nadler LM. The role of B7-1/B7-2:CD28/CLTA-4 pathways in the prevention of anergy, induction of productive immunity and down-regulation of the immune response. Immunol Rev 1996; 153: 5-26.
9. June CH, Bluestone JA, Nadler LM, Thompson CB. The B7 and CD28 receptor families. Immunol Today 1994; 15: 321-331.
10. Tamada K, Harada M, Okamoto T, Takenoyama M, Ito O, Matsuzaki G, Nomoto K. Specific antitumor activity of tumor-infiltrating lymphocytes expanded first in a culture with both anti-CD3 monoclonal antibody and activated B cells and then in a culture with interleukin-2. Cancer Immunol Immunother 1995; 41: 339-347.
11. Suvas S, Singh V, Sahdev S, Vohra H, Agrewala JN. Distinct role of CD80 and CD86 in the regulation of the activation of B cell and B cell lymphoma. J Biol Chem 2002; 277: 7766-7775.
12. Terrazzano G, Zanzi D, Palomba C, Carbone E, Grimaldi S, Pisanti S, Fontana S, Zappacosta S, Ruggiero G. Differential involvement of CD40, CD80, and major histocompatibility complex class I mole-cules in cytotoxicity induction and interferon-gamma production by human natural killer effectors. J Leukoc Biol 2002; 72: 305-311.
13. Lanier LL, O'Fallon S, Somoza C, Phillips JH, Linsley PS, Okumura K, Ito D, Azuma M. CD80 (B7) and CD86 (B70) provide similar costimulatory signals for T cell proliferation, cytokine production, and generation of CTL. J Immunol 1995; 154: 97-105.
14. Rao KL, Varalakshmi C, Kumari AL, Khar A. Interaction between B.7 and CD28 costimulatory molecules is essential for the activation of effector function mediating spontaneous tumour regression. Scand J Immunol 1999; 49: 633-640.
15. Kim CW, Choi SH, Chung EJ, Lee MJ, Byun EK, Ryu MH, Bang YJ. Alteration of signal-transducing molecules and phenotypical char-acteristics in peripheral blood lymphocytes from gastric carcinoma patients. Pathobiology 1999; 67: 123-128.
16. Dell'Agnola C, Biragyn A. Clinical utilization of chemokines to combat cancer: the double-edged sword. Expert Rev Vaccines 2007; 6: 267-283.
17. Salazar-Onfray F, Lopez MN, Mendoza-Naranjo A. Paradoxical effects of cytokines in tumor immune surveillance and tumor immune escape. Cytokine Growth Factor Rev 2007; 18: 171-182.
18. Zeng Z, Xu X, Zhang Y, Xing J, Long J, Gu L, Wang X, Sun D, Ka W, Yao W, Wen Z, Chien S. Tumor-derived factors impaired motility and immune functions of dendritic cells through derangement of biophysical characteristics and reorganization of cytoskeleton. Cell Motil Cytoskeleton 2007; 64: 186-198.
19. Ogasawara K, Yoshinaga SK, Lanier LL. Inducible costimulator costimulates cytotoxic activity and IFN-gamma production in acti-vated murine NK cells. J Immunol 2002; 169: 3676-3685.
20. Hayakawa Y, Takeda K, Yagita H, Kakuta S, Iwakura Y, Van Kaer L, Saiki I, Okumura K. Critical contribution of IFN-gamma and NK cells, but not perforin-mediated cytotoxicity, to anti-metastatic effect of alpha-galactosylceramide. Eur J Immunol 2001; 31: 1720-1727.
21. Oliver AM, Martin F, Kearney JF. IgMhighCD21high lymphocytes enriched in the splenic marginal zone generate effector cells more rapidly than the bulk of follicular B cells. J Immunol 1999; 162: 7198-7207.
22. Michael A, Hackett JJ, Bennett M, Kumar V, Yuan D. Regulation of B lymphocytes by natural killer cells. Role of IFN-gamma. J Immunol 1989; 142: 1095-1101.
23. Hayakawa Y, Takeda K, Yagita H, Smyth MJ, Van Kaer L, Okumura K, Saiki I. IFN-gamma-mediated inhibition of tumor angiogenesis by natural killer T-cell ligand, alpha-galactosylceramide. Blood 2002; 100: 1728-1733.
24. Kelly JM, Takeda K, Darcy PK, Yagita H, Smyth MJ. A role for IFN-gamma in primary and secondary immunity generated by NK cell-sensitive tumor-expressing CD80 in vivo. J Immunol 2002; 168: 4472-4479.
25. Fujii S, Shimizu K, Kronenberg M, Steinman RM. Prolonged IFN-gamma-producing NKT response induced with alpha-galactosylceramide-loaded DCs. Nat Immunol 2002; 3: 867-874.
26. Luque I, Reyburn H, Strominger JL. Expression of the CD80 and CD86 molecules enhances cytotoxicity by human natural killer cells. Hum Immunol 2000; 61: 721-728.
27. Chambers BJ, Salcedo M, Ljunggren HG. Triggering of natural killer cells by the costimulatory molecule CD80 (B7-1). Immunity 1996; 5: 311-317.
28. Geldhof AB, Raes G, Bakkus M, Devos S, Thielemans K, De Baetselier P. Expression of B7-1 by highly metastatic mouse T lymphomas induces optimal natural killer cell-mediated cytotoxicity. Cancer Res 1995; 55: 2730-2733.
29. Yeh KY, Pulaski BA, Woods ML, McAdam AJ, Gaspari AA, Frelinger JG, Lord EM. B7-1 enhances natural killer cell-mediated cytotoxicity and inhibits tumor growth of a poorly immunogenic murine carcinoma. Cell Immunol 1995; 165: 217-224.
30. Barlozzari T, Leonhardt J, Wiltrout RH, Herberman RB, Reynolds CW. Direct evidence for the role of LGL in the inhibition of experi-mental tumor metastases. J Immunol 1985; 134: 2783-2789.
31. Simecka JW, Patel P, Davis JK, Ross SE, Otwell P, Cassell GH. Spe-cific and nonspecific antibody responses in different segments of the respiratory tract in rats infected with Mycoplasma pulmonis. Infect Immun 1991; 59: 3715-3721.
32. Jones HP, Hodge LM, Fujihashi K, Kiyono H, McGhee JR, Simecka JW. The pulmonary environment promotes Th2 cell responses after nasal-pulmonary immunization with antigen alone, but Th1 responses are induced during instances of intense immune stimula-tion. J Immunol 2001; 167: 4518-4526.
33. Kruisbeek AM. Introduction: regulation of T cell development by the thymic microenvironment. Semin Immunol 1999; 11: 1-2.